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Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystemic involvement presenting with numerous clinical manifestations (Kaul et al., 2016; Rahman and Isenberg, 2008) . Neuropsychiatric systemic lupus erythematosus (NPSLE) involves neurologic manifestations seen in the central, peripheral, and autonomic nervous systems as well as psychiatric disorders in patients with SLE in which other causes have been excluded (Monahan et al., 2017; Pikman et al., 2017; Unterman et al., 2011; Zirkzee et al., 2014) . Extensive research into the pathogenesis of NPSLE has been conducted, with the identification of many potential contributing factors, including autoantibodies (such as anti-NMDA receptors, anti-GABA receptors, anti-ribosomal P and anti-U1 RNP et. al) (Gonzalez and Massardo, 2018; Karaaslan et al., 2017; Pisetsky, 2016; Sato et al., 2010; Tsuchiya et al., 2014; Viana et al., 2017) , cytokines and chemokines in the serum of SLE patients (Ho et al., 2016; Hu et al., 2015; Jeltsch-David and Muller, 2014; Okamoto et al., 2010) . Because of the protection of the blood-brain barrier (BBB), the CNS is traditionally regarded as an immunologically privileged site (Muldoon et al., 2013) . The immune microenviroment in CNS is quite different from peripheral tissues.
The immunological mechanisms of how the serum of SLE induces inflammatory responses in CNS a valuable research issue.
Microglia is a kind of innate immune cell in the CNS, which functions as first-line responders under inflammatory conditions. Once activated, microglia release cytokines pro-inflammatory molecules and reactive oxygen radicals, which can ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T
modulate astrocytes and neurons in a paracrine manner, and also affect microglia in an autocrine fashion by either positive or negative feedback loops (Kabba et al., 2018; Li and Barres, 2017) . Activation of microglia has been implicated in the inflammatory responses in neurological and psychological diseases such as Alzheimer 's disease,
Parkinson's disease, multiple sclerosis and stress (Clayton et al., 2017; Gentile et al., 2015; Slusarczyk et al., 2015; Subramaniam and Federoff, 2017; Wachholz et al., 2016) . Animal studies on MRL-lpr mice, a model of NPSLE, also reported an increase of microglia activation with age (Ballok et al., 2006) . Targeting microglia activation has been proposed as an effective strategy to treat neuroinfammatory diseases (Subramaniam and Federoff, 2017) . Recently, we observed that stimulation of microglia cultures with serum collected from SLE patients could induce the activation of microglia, indicated by obvious morphological changes, increased expression of MHC II and CD86 protein, and overproduction of proinflammatory cytokines (Wang et al., 2017) .
Based on our findings and previous knowledge, we hypothesize that inflammatory factors in serum of SLE patients may trigger an activation of microglia that results in imbalance of immunity hemostasis in CNS and the recruitment of immune cells. To test this hypothesis, we performed intracerebroventricular (ICV) injection of serums collected from SLE patients or healthy controls into mice. We examined phenotypic changes of microglia in the cortex and hippocampus, and measured the levels of cytokines, chemokine and adhesion molecules. To test whether ICV injection of SLE serum can promote the recruitment of blood circulating
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A C C E P T E D M A N U S C R I P T leukocytes, we used intravital microscopy to observe leukocyte rolling and adhesion in the cerebromicrovasculature. We further examined whether minocycline, an established microglial inhibitor (Bhandare et al., 2017; Bi et al., 2016; Stokes et al., 2017) , can block inflammatory responses induced by SLE serum. We will provide evidence suggesting that an SLE-serum-induced activation of microglia is involved in the neuroinflammation in SLE and minocycline may be able to attenuate or dampen this potentially detrimental response.
Materials and methods
Animals
Experiments were performed using 8-12 weeks-old C57BL/6 male mice (Vital River Laboratory, Beijing, China). All animals were maintained in standard animal cages under conventional laboratory conditions (12 h/12 h light/dark cycle, 22 °C) with ad libitum access to food and water. The animals were maintained and treated in compliance with the policies and procedures detailed in the "Guide for the Care and Use of Laboratory Animals" of the National Institutes of Health. The animal experimental protocols of the "Guide" and the treatment procedures were reviewed and approved by the Animal Care and Use Committee of China Medical University (No. KT2018060). All surgeries were performed under anesthesia, and all efforts were made to minimize animal suffering.
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3.71 and urea 6.7, pH 7.4]. Injection (1 µl at the rate of 0.4 µl/min) was conducted by cannulae PE tubing (# 62302, RWD Life Science) connected to a 10 µl Harvard Apparatus syringe pump system (Pump 11 Elite). The tubing was left in place for another 5 min at the end of injection, and the cannulae capped to prevent reflux of the injected solution.
Minocycline administration
Minocycline hydrochloride (#M9511; Sigma, St. Louis,MO, USA) was dissolved fresh in 0.9 % NaCl and administered intragastrically (i.g.) at a dosage of 90 mg/kg body weight at 2 h prior to the ICV injection. The dose was selected on the basis of previous studies showing the beneficial effects of this dosage in animal models of cerebral brain ischemia, multiple sclerosis, and Parkinson's disease (Popovic et al., 2002; Wu et al., 2002; Yrjanheikki et al., 1998) .
Intravital microscopy in mouse brain
Intravital microscopy of the mouse cerebromicrovasculature was performed as previously described (dos Santos et al., 2005) . For this, a cranial window (2mm in diameter) was opened using a high-speed drill (#78001, RWD Life Science) after implanted the canulae in lateral ventricle. A piece of cover glass (0.13 mm thick, Citotest, Haimen, China) was lowered on top of the dura, and dental cement was applied to the perimeter of the craniotomy to fix it. Animals were allowed to recover for 1 week. On the day of experiment, the mice were anesthetized by 1.5% isoflurane and the tail vein was cannulated for administration of fluorescent dyes. Blood flow in the cerebromicrovasculature was observed through the implanted glass window.
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Throughout the experiment, the mouse was maintained at 37.8℃ with a heating pad and the exposed brain was continuously superfused with ACSF at 37.8℃. Leukocytes were fluorescently labeled by i.v. administration of rhodamine 6G (0.5 mg/kg body weight) and observed using a microscope (NE900, X20 objective lens, Novel, Zhejiang, China) outfitted with a fluorescent light source (epi-illumination at 510-560 nm, using a 590-nm emission filter). A silicon-intensified camera (MS55, Mshot, Guangzhou, China) mounted on the microscope projected the image onto a monitor.
Rolling leukocytes were defined as white cells moving at a velocity less than that of erythrocytes cells. Leukocytes were considered adherent to the venular endothelium if they remained stationary for 30 s or longer.
Brain histology
After intravital microscopy observation, mice were sacrificed and extensively perfused with cold PBS. Brains were dissected into right and left hemispheres. The left hemisphere of the brain was fixed in 4% paraformaldehyde for 24 h at 4 ℃. The right brain hemisphere was snap-frozen for RNA extraction. At least 24 h before sectioning, the fixed brains were transferred to a 20% sucrose (w/v) solution for cryoprotection. Coronal sections of 10µm were cut on a freezing microtome, mounted on gelatin-coated slides.
Immunofluorescence
For immunofluorescence staining, sections were incubated with one of the following antibodies: Iba-1 (1：100,ab178847,Abcam), P-selectin (1：80,SC-8419, Santa Cruz) or ICAM-1 (1：250, ab119871, Abcam) followed by the secondary
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qRT-PCR
Total RNA was isolated from the brain of the mice using a TRizol RNA Extraction kit (MM032, ProbeGene, Jiangshu, China). cDNA synthesis was performed with the first strand synthesis kit (MM061, ProbeGene, Jiangshu, China).
qRT-PCR was performed in triplicate for IL-1β, IL-6, TNF-α, CCL2, CCL5, ICAM-1, P-selectin. The primer sequences were as follows: 1) GAPDH: (forward)
GTCAAGGCCGAGAATGGGA, (reverse) GCAGAAGGGGCGGAGATG 2) IL-1β:
TCATCTCGGAGCCTGTAGTGC ; 3) IL-6: (forward) CCATCCAGTTGCCTTCTTGG, (reverse) GGTCTGTTGGGAGTGGTATCCTC; 4)
TCAGGGAAGAATCTGGAAAGGT; 5) CCL2:
GTGCTGACCCCAAGAAGGAA, (reverse) GGTGGTTGTGGAAAAGGTAGTG; 6)
GCGAGTTGGCTCCCCTGA.
PCR was performed using LineGene9600 PCR System (Bioer, Hangzhou, China).
Amplification started with an initial denaturation step at 95 ℃ for 10 min, followed by gene-specific cycles of denaturation at 95 ℃ for 15 s, specific annealing for each gene for 30 s, and extension at 60 ℃ for 30 s. GAPDH was used as reference gene. The relative expression of target gene was calculated as ∆Cq=Cq gene -Cq reference, and the fold change of target gene expression was calculated by the 2 -∆∆ Cq method.
Primary microglia cultures and detection the binding of IgGs by immunofluorescence
Primary microglia were derived from postnatal C57BL/6 mice (P1-P3), using the "low concentration trypsin digestion" method. Briefly, cerebral cortices were devoid of meninges and blood vessels, dissected in Hank's salt (HBSS) and trypsinized with 0.125% trypsin-EDTA and 1ug/ml DNase I for 30 min at 37 °C. The mixed glial culture was incubated in DMEM/F-12 containing 10% fetal bovine serum (FBS) and 100 U/ml penicillin/streptomycin (PS) and seeded at 7.5× 10 6 -10 × 10 6 cells per 75 cm 2 flask. After 8-13 days, microglia were separated from the mixed primary culture by trypsinized with 0.125% trypsin-EDTA for 20 min at 37 °C. The media were collected and centrifuged at 1000 rpm for 6 min to obtain a pellet of microglia.
Thereafter, cells were plated at 1 × 10 5 cells/well in 24-well plates precoated with poly-L-lysine (30 ug/ml). Purity of microglia (above 95%) was confirmed by ACCEPTED MANUSCRIPT
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immunofluorescence staining with anti-iba1 antibody.
Microglia were seeded in 24-well culture plates until 90% confluence. The cells were incubated with 100μg/ml of IgG from SLE patients or from healthy control in a 5% CO 2 incubator at 37°C overnight. Thereafter, 
Cytokine assay to evaluate the microglia response to IgG stimulation
Microglia cells were seeded into 96-well plates at a density of 2 × 10 4 cells/well.
After 24 h of incubation, 100μg/ml of IgG from SLE patients or from healthy control were added to the plates. Twenty four hours later, supernatants of microglia cultured under different conditions were collected and centrifuged at 10,000 ×g for 10 min at ACCEPTED MANUSCRIPT
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4 °C to remove cell debris. The supernatants were stored in aliquots at −80 °C prior to use. IL-1β, IL-6, and TNF-α were measured in the culture supernatants by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (R & D Systems, Minneapolis, MN, USA). All treatments were completed eight times, and the data were expressed as the mean pg/ml ± SEM.
Statistical analysis
SPSS 18.0 software (SPSS Inc., Chicago, IL, USA) was used to perform the statistical analysis. Each graph depicts the mean ± standard error of the mean.
Differences in the immunohistochemical data and q RT-PCR results were detected by
Student's t-test or one-way analysis of variance (ANOVA). Each ANOVA reporting significant effects was followed by Tukey's post hoc test of multiple comparison. A p value of <0.05 was considered statistically significant.
Results
ICV injection of SLE-serum induces microglia activation
Twenty-four mice, randomly divided into 3 groups, were administered by a single ICV injection of SLE sera or health sera or vehicle, respectively. The mice had no any obvious signs of sickness within 24 hours after ICV injection. We gauged and compared the distribution of cells immunoreactive for the microglial (Iba-1) markers in the cortex and hippocampus of mice at 24 hours after received ICV injection. The activated state of microglia was judged by phenotypic changes and increase in cell number. Iba-1 protein expressed on the cell surface is prevalently used to study the activated states (Imai et al., 1996; Patro et al., 2010) Cell quantification of Iba-1 immunopositive cells revealed that Iba-1+ cell count in the cortex and CA1 hippocampus of SLE-serum treated mice was significantly higher than those in the healthy-serum and vehicle treated mice (Fig.1G, ANOVA followed by Tukey's post hoc test), and there was no significant difference between the healthy-serum and vehicle treated mice.
SLE-serum promotes leukocyte recruitment into the brain
We used intravital microscopy to directly visualize the leukocyte -endothelial cell interaction in the cerebromicrovessels before and 24 h after vehicle, SLE-or healthy-serum administration ( Fig. 2A-F) . Negligible numbers of both rolling leukocytes ( Fig. 2G ) and adherent leukocytes (Fig. 2H) were noted under control condition. After SLE-serum injection, the number of rolling and adherent cells increased 8-fold ( Fig. 2G and H) . Such a change was not observed in the mice treated by healthy-serum.
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SLE-serum induced endothelial activation in the brain microvasculature
A key event in leukocyte recruitment is the ability of the endothelium to express cellular adhesion molecular to allow for leukocyte rolling. To test whether endothelium in the CNS was activated after ICV injection of SLE-serum, ICAM-1 and P-selectin expression in the brain was measured using immunofluorescence staining. As shown in Fig. 3 , although very little ICAM-1 and P-selectin expression was noted in the brain microvasculature of vehicle- (Fig. 3A and B ) and healthy-serum treated mice ( Fig. 3C and D) , an increase in ICAM-1 and P-selectin expression was observed in the SLE-serum treated mice ( Fig. 3E and F) . Clearly, SLE-serum induced endothelium activation in the brain.
SLE-serum injection up-regulated the production of cytokines and chemokines
We also examined the levels of cytokines and chemokines in the brain tissues using qRT-PCR analysis and found that the mRNA expression of IL-1β, IL-6, TNF-α, CCL2 and CCL5 was up-regulated by SLE-serum injection (Fig. 4) .
Minoncyline inhibited SLE-serum induced microglia activation and leukocytes recruitment
Minocycline has been reported by many groups to be an effective inhibitor for microglial activation, which can rapidly cross the blood-brain barrier (Bhandare et al., 2017; Bi et al., 2016; Stokes et al., 2017) . We used a subset of mice to examine whether minocycline can inhibit the microglia activation in response to ICV administration of SLE-serum and suppress the subsequent inflammatory responses.
The first group of mice (n = 5) received an i.g. administration of minocycline (90
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mg/kg, dissolved in saline) at 2 h before ICV injection of SLE-serum (minocycline + SLE-serum group). The second group (n = 5) received the same dose of saline and SLE-serum as the control group (Saline + SLE-serum group). The third group (n = 5) received only minocycline without the SLE-serum injection (minocycline group). We found that pretreatment of minocycline effectively inhibited the morphological changes and proliferation of microglia induced by ICV injection of SLE-serum (Fig.5) .
Minocycline treatment dramatically reduced leukocyte rolling and adhesion (Fig.6) , and the expression of ICAM-1 and P-selectin (Fig.7) . The increases in the mRNA expression of IL-1β, IL-6, TNF-α, CCL2 and CCL5 caused by SLE-serum stimulation were also largely inhibited by pretreatment of minocycline (Fig. 8 ).
In vitro experiments indicate that IgG in SLE-serum induce microglia activation
Above results raise a question of what factors in the SLE-serum cause the effect of microglia activation. One reasonable deduction is that immune complexes may play a role in the microglia activation. To test this, we isolated IgG from the pooled patient sera, and examined its effects on primary cultured microglia. IgG from pooled normal sera was used as control. Histochemical staining revealed that both patient and normal IgGs could bind with the microglia, and were engulfed by the microglia (Fig. 9 A and B) . However, the expression levels of pro-inflammatory cytokines were significantly higher in the microglia stimulated by SLE IgG than in those stimulated by normal IgG (Fig.9C -E) . This result suggests that the microglia were activated after they engulfed the IgG from the SLE sera, while the microglia engulfed normal IgG were not activated.
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Discussion
In the present study, we aimed to examine whether the circulating serum of SLE patients can evoke microglia activation and inflammatory reaction in the CNS. We found that ICV administration of SLE-serum induced a morphological change of microglia from ramified to activated states, and up-regulated the expression of IL-1β, IL-6, TNF-α, CCL2 and CCL5 in the brain. Intravital microscopy also revealed an increase of leukocyte rolling and adhesion in the brain microvasculature, which may associate with an elevated expression of ICAM-1 and P-selectin on the blood vessels.
We further found that pretreatment with minocycline to inhibit microglia activation effectively suppressed the up-regulation of cytokine and chemokine expression, and inhibited the leukocyte rolling and adhesion. The in vitro experiments revealed that the activation of microglia may be attributable to IgG in the SLE sera. Our data suggests that SLE-serum can induce a series of inflammatory responses in CNS, and microglia play a key role in this process.
As the major immune cell type resident in the brain, microglia continuously scans the extracellular brain environment and becomes activated in response to various inflammatory stimuli, which may further lead to abundant cytokine production or phagocytosis of cellular debris (Kabba et al., 2018; Li and Barres, 2017) . Microglial activation takes place in various neurological disorders including CNS and peripheral infections, neurodegenerative diseases, traumatic brain injury, ischemic and hemorrhagic stroke (Doens and Fernandez, 2014; Dudvarski Stankovic et al., 2016; Hernandez-Ontiveros et al., 2013; Puntener et al., 2012) . Microglia activation was
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also found in the brain of animal model of NPSLE (Ballok et al., 2006) . Previously, we have observed that SLE-serum could activate the cultured microglia in vitro (Wang et al., 2017) . The microglia activated by SLE-serum showed thick processes and large irregular soma, and released more proinflammatory cytokines IL-1β, IL-6, and TNF-α. However, due to the biological complexity of neurological homeostasis, it
is not enough just to study glia in isolation from their extracellular environment. We need to understand how changes in the brain microenvironment trigger glial activation and inflammatory activity in brain tissues. Here, we directly injected the SLE-serum into the lateral ventricle of healthy mice to examine the effect of SLE-serum on microglia. Consistent with the results of in vitro observations, we found that SLE-serum could activate the microglia under in vivo condition. It should be mentioned that the activation of microglia was accessed by immunofluorescence stain of Iba-1, which is upregulated during microglia reactive responses (Ito et al., 1998) .
Iba-1 has been established as a microglial marker, and frequently used for immunohistochemical identification of microglia. However, Iba-1 is widely expressed by myeloid cell types (Prinz and Priller, 2014; Prinz et al., 2011) , meaning that the immunohistochemical antibodies against Iba-1 cannot discriminate microglia from CNS-infiltrating macrophages. Microglia-specific markers have not been well defined until recently. Although expressions of some molecules (such as TMEM119)
have been found to restrict to microglia in the CNS, these markers are not fully specific. For example, TMEM119 expression is absent in immature microglia (Bennett et al., 2016) . Because in the intravital image experiments we just observed ACCEPTED MANUSCRIPT
that leukocytes rolled and adhered to the vessel wall (Fig. 2) , no obvious leukocyte infiltration was found, the number of infiltrating macrophages in our Iba-1 positive cells may not be large.
It has been well established that activated microglia can produce proinflammatory cytokines (Wang and Dore, 2007) and chemokines (Matsushita et al., 2000) . Indeed, we observed a significant increase in the expression of IL-1β, IL-6, TNF-α, CCL2 and CCL5 in the SLE-serum-treated brain. These up-regulated cytokines and chemokines may contribute to leukocyte recruitments into CNS. The proinflammatory cytokines, such as TNF-α, have been proved to be able to stimulate endothelium to cause an increase in adhesion molecule expression Rajan et al., 2008) . To migrate into sites of inflammation, leukocytes must first tether and roll along the vessel before they firmly adhere and emigrate out of the vasculature (Kerfoot and Kubes, 2002; McCafferty et al., 2000) . Firm adhesion is mediated by the expression of adhesion molecules and their ligands on the surface of leukocytes.
ICAM-1 and P-selectin are typical adhesion molecules that participate in leukocytes rolling and adhesion (Broide et al., 1998; Su et al., 2012) . Indeed, our results showed that the expressions of ICAM-1 and P-selectin were elevated by SLE-serum treatment.
Moreover, chemokines such as CCL2 and CCL5 produced by microglia have chemotactic activity on leukocyte. Firm adhesion between leukocytes and endothelium cells is triggered by the action of the chemoattractant molecules (dos Santos et al., 2005) .
Using in vivo imaging, we demonstrated that SLE-serum can promote leukocyte ACCEPTED MANUSCRIPT
rolling and adhesion in the brain microvasculature. In vivo imaging is a non-invasive method, which has been well used to observe the dynamic of cell function in CNS and has provided invaluable insights for the cellular mechanisms of disease onset and progression (Adams et al., 2007; Davalos et al., 2012; Ryu et al., 2015) . An advantage of in vivo imaging over immunohistochemical staining is to continuously observe the pathological changes in the same subject. Taken our immunohistochemical and in vivo imaging results together, we propose that microglia activation plays a key role in SLE-serum induced inflammatory response, that is, SLE-serum induces an activation of microglia, and the activated microglia release amount of proinflammatory cytokines and chemokines, which then trigger leukocyte recruitment into the CNS.
The essential pathophysiological role of microglia in SLE-serum-induced inflammation suggests that inhibition of microglia activation may have therapeutic potential. Minocycline, a tetracycline derivative, has been reported to block LPS-induced microglial release of cytokines, inducible NO synthase production, and oxidant production in vitro (Wang et al., 2005) . Because minocycline has surprising ability to penetrate the blood-brain barrier (Zhu et al., 2002) , studies on animal models have found some remarkable protective effects of minocycline against neurodegenerative diseases, including Huntington's disease (Kumar et al., 2013 ),
Parkinson's disease (Thomas and Le, 2004) , and Alzheimer 's disease (Budni et al., 2016) , and brain injuries caused by trauma (Haber et al., 2017) or ischemia/reperfusion (Jin et al., 2015) . Our data provide further information on minocycline's inhibitory effects on microglia. Also, leukocyte rolling and adhesion
induced by SLE-serum administration were attenuated by minocycline. However, it should be noted that minocycline is also an inducer of lupus in humans (Sarzi-Puttini et al., 2005) . We used minocycline in this animal study just to prove that inhibition of microglia activation is a potential way to modulate or dampen the neuroinflammation associated with SLE. Finding other safe tetracyclines or antibiotics that are protective for microglia and cross the BBB is a clinically significant issue.
There is still an important question to be addressed in the future, that is, what are the molecular links between increased BBB leakage, microglia activation and inflammation? Previous studies have revealed a number of factors associated with neurological disorders in the circulating blood of SLE patients, including autoantibodies (anti-phospholipid, anti-ribosomal P and anti-DNA antibodies) and cytokines (IL-2, IL-6, IL-8, IL-10, IFN-α, and TNF-α) (Abe et al., 2017; DeGiorgio et al., 2001; Efthimiou and Blanco, 2009; Ho et al., 2016; Segovia-Miranda et al., 2015) .
Some of these immunological mediators may contribute to the initial disruption of BBB by acting on vascular endothelial cells (Abbott et al., 2003; Jacob et al., 2010; Stock et al., 2013; Wen et al., 2015; Wen et al., 2013) . Leakage of BBB can cause more serum proteins enter CNS, which then promote microglial activation, inflammatory mediator production and leukocyte recruitment in a positive feedback loop. The limitation of this study is lack of proof of specific factors for microglia activation in SLE-serum. The results of in vitro experiments showed that IgG of SLE patients could be engulfed by the microglia, and stimulated the microglia to produce pro-inflammatory cytokines. Limited by the volume of samples, we could not purify
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Conclusion
Our study suggests that microglia in the brain can detect the pathological factors in the SLE-serum and release cytokines that activate the endothelium to recruit leukocytes. Although it is an important immune response to internal environment changes, if the inflammatory response is too robust, neuron injury can also occur and nervous functions may be damaged. Our data also demonstrate that minocycline can significantly reduce the inflammatory response, raising the possibility that this drug could be used to relieve NPSLE if and when necessary.
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Figure legends
SLE-serum alone (E) -(F).
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The healthy control group consisted of 1 men and 16 women wi th a mean ± SD, a ge of 29.9 ± 9.3 yea rs . SLEDAI:
s ystemi c lupus erythematosus (SLE) disease acti vi ty index; CRP: C-rea cti ve protein; ESR: erythrocyte s edimentation ra te; C3 a nd C4: complements 3 a nd 4.  SLE serum promotes leukocyte rolling and adhesion.
Graphical abstract
 Suppression of microglia activation prevents leukocyte rolling and adhesion.
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